Annuncio • Feb 21
Biostax Corp. Intends to Voluntary Delist Common Stock from OTC Pink Marketplace On February 19, 2025, Biostax Corp. (the "Company") notified the Securities and Exchange Commission (the "SEC") of the Company's intention to voluntarily file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934). The Company intends to file the Form 25 with the SEC on or about February 26, 2025 to effect the voluntary delisting of the Company's common stock from the OTC Pink marketplace and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This decision to voluntarily delist and deregister was made by the Company's Board of Directors after careful consideration of the advantages and disadvantages of being a public reporting company. The Company is eligible to deregister its common stock as its assets are substantially below $10 million. As of November 20, 2024, the Company's total assets were approximately $6.669,000 million. The Board has determined that the costs and expenses associated with being a public reporting company outweigh the benefits to the Company and its stockholders at this time. It is important to note that this action is entirely voluntary and was not requested or demanded by any regulatory body or exchange. The Company anticipates that its obligation to file periodic reports and other information with the SEC will be suspended upon the effective date of Form 25. The Company intends to file a Form 15 with the SEC on or about February 26, 2025, to suspend its duty to file reports under Sections 13 and 15(d) of the Exchange Act. Annuncio • Aug 15
Biostax Corp. announced delayed 10-Q filing On 08/14/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • May 17
Biostax Corp. announced delayed 10-Q filing On 05/15/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Apr 02
Biostax Corp. announced delayed annual 10-K filing On 04/01/2024, Biostax Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Nov 17
Biostax Corp. Appoints Craig Suro as a Director Biostax Corp. announced the appointment of Influential Business Leader Roger “Craig” Suro as Director. Renowned Virginia native, Mr. Suro, has emerged as a driving force in the realms of business innovation, public policy, and community revitalization. With an extensive background in business development and public service, Mr. Suro has continually spearheaded transformative initiatives that have left a lasting impact on Virginia's economic landscape. Mr. Suro's journey began as Virginia’s Assistant Secretary of Health and Human Resources under the office of Secretary Jane Woods where he exhibited exceptional leadership in policy coordination, legislative affairs, and relationship building with state healthcare agencies. His expertise in healthcare policies laid the foundation for his venture into the private sector, where he co-founded Caretime LLC in 2010. This private healthcare software company, under Mr. Suro's guidance, achieved remarkable success, experiencing an average annual revenue growth of 52%. Recognized for his entrepreneurial acumen, Mr. Suro ventured into the aquaculture industry in 2014, founding the not-for profit, Tangier Island Oyster Company. His vision revitalized the economy of Tangier Island, providing over 1 million premium brand oysters annually to select restaurants creating a range of new employment opportunities and establishing a sustainable market for premium oysters. In recent years, Mr. Suro's focus has shifted towards the burgeoning field of Biotechnology. Collaborating with leading companies in the Richmond/Petersburg region, he has been instrumental in driving innovative drug research and manufacturing projects. His consultancy work ensures that these initiatives maximize growth, fostering synergies that benefit communities, national safety, and public health. Mr. Suro's dedication to community development is reflected in his service on several boards and committees. He serves on the Greater Richmond YMCA Board and currently volunteers on the Property and Facilities committee. Presently, he serves on the HCA Central Division Region Market Advisory Committee, the Community Board for Blue Ridge Bank, and the Board of Trustees for The Steward School. With a legacy marked by innovation, collaboration, and community empowerment, Craig Suro continues to shape Virginia's future. His dynamic approach and visionary leadership make him a driving force behind transformative change, leaving an indelible mark on businesses, communities, and industries alike. Annuncio • Nov 03
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors Biostax Corp. announced the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys &Girls Clubs of Richmond, St. Marys Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond. In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a fundraising professional, showcasing an unwavering passion for aiding not-for-profit organizations in realizing their missions. With an impressive track record, she has adeptly secured substantial financial contributions and cultivated robust donor networks. She has taken on pivotal roles, serving on and chairing various committees such as the Organizations Development or Advancement Committee, the Capital Campaign Committee, and the Governance and Executive Committee. Her expertise has shined through as she has successfully assumed the role of Tournament Director for numerous Charity Golf Events, Banquets, and Auctions. Early in her career, Ms. Caperton served as the Assistant Marketing Manager for the Richmond Braves, the AAA Franchise of the Atlanta Braves. Subsequently, at Sports Development League (SDL), she honed her resourcefulness, flexibility, and adeptness in dealing with diverse personalities. These invaluable skills laid the foundation for her future roles in event management. Mrs. Capertons impact extended to the academic sphere as well. Collaborating with Virginia Commonwealth University, she played a pivotal role in the development of a Sports Marketing Graduate Program, overseeing internships, and contributing to the formulation of event management and operations curricula. Furthermore, her outstanding reputation led to her appointment as the Director of the Henrico County Open on the Nationwide Tour by The PGA Tour. Over six years, she adeptly managed this televised event, showcasing her unwavering dedication to excellence and organizational prowess. Mrs. Capertons multifaceted career stands as a testament to her unwavering commitment to excellence, innovation, and impactful contributions to both the sports and not-for-profit sectors. Annuncio • Aug 17
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih Immune Therapeutics, Inc. d/b/a Biostax Corp. announced that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-122 and the U.S. Food and Drug Administration (FDA) has finalized those transfers. The INDs that were transferred to Biostax include IND 146955 for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, IND 147347 for the treatment of Nonalcoholic Liver Disease (NAFLD) and IND 127303 for the treatment of Autoimmune Hepatitis along with the Orphan Designation for Autoimmune Hepatitis. These INDs were transferred from TaiwanJ Pharmaceuticals, who licensed the development and commercialization of JKB-122 to Biostax Corp. in 2022. JKB-122 is a small molecule and a long-acting TLR4 antagonist that has been shown to play a prominent role in the pathogenesis of certain autoimmune and inflammatory conditions including the treatments of chronic liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Hepatitis (AIH), and Non-Alcoholic Steatohepatitis (Nash). Annuncio • Jan 04
Immune Therapeutics, Inc. Announces Director Resignations Immune Therapeutics, Inc. announced that on December 15, 2022, Kevin Phelps, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Mr. Phelps resigned from his position as a director of the Company, effective December 31, 2022. Mr. Phelps’ resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies or practices of the Company. On December 17, 2022, Dr. Roscoe Moore, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Dr. Moore resigned from his position with the Company, effective on December 31, 2022. Dr. Moore’s resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies, or practices of the Company. Annuncio • Sep 28
Immune Therapeutics, Inc. Appoints H. Louis Salomonksy to Its Board of Directors Immune Therapeutics, Inc. announced the appointment of Louis Salomonsky to the Company's Board of Directors. Mr. SalomonskyLouis Salomonsky is a real estate professional with decades of experience designing, developing, and managing commercial real estate. Mr. Salomonsky's firm, Historic Housing LLC, has expertise in the adaptive reuse of historic buildings, as well as the construction of new buildings for multi-family residential. Mr. Salomonsky works in two dynamic property markets, namely Richmond, Virginia and Washington, DC, creating assets collectively valued by Mr. Salomonsky's firm at $750 million, over the past 28 years. Mr. Salomonsky's firm specializes in federal Low-Income Housing Tax Credits and historic rehabilitation tax credits, and conventionally financed three to twelve-story market rate new-construction buildings.Mr. Salomonsky has a long track record of community and professional volunteerism including serving on task forces examining historic tax credit legislation for the Commonwealth of Virginia and the government structure of the City of Richmond. Mr. Salomonsky has served as the Vice Rector and as a Member of the Board of Visitors for Virginia State University. He currently serves on the UVA School of Architecture Foundation Board. Annuncio • Sep 01
Immune Therapeutics, Inc. announced a financing transaction Immune Therapeutics, Inc. announced that it will receive $5,000,000 in funding on August 31, 2022. The company will issue non-convertible debt in the transaction. The minimum investment accepted from any outside investor is $25,000. The company will issue securities pursuant to exemption provided under Regulation D. Annuncio • Aug 10
Immune Therapeutics, Inc. announced delayed 10-Q filing On 08/09/2022, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Aug 03
Immune Therapeutics, Inc. announced that it has received $0.4 million in funding On August 2, 2022, Immune Therapeutics, Inc. closed the transaction. The transaction included participation from single investor. Annuncio • Jul 23
Immune Therapeutics, Inc. Announces Chief Executive Officer Changes Immune Therapeutics, Inc. announced the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors. Dr. Wilson brings over 20 years of experience in biomedical research, executive management, and corporate governance. He is a trained immunologist. In addition, he is, among other things, an Associate Clinical Professor at the University of California, San Diego, and he previously served as the Chief Operating Officer at the La Jolla Institute for Immunology as it grew to become an international powerhouse. Immune also announced that Kevin Phelps has stepped down from his positions as the company’s CFO, President, and CEO, but he will remain a member of Immune’s Board of Directors. The appointment of Dr. Wilson as Immune’s CEO, President, and interim CFO is expected to further strengthen IMUN’s global executive leadership team to drive its next phase of growth and operational success within a new operational model, initially focused on regulatory approval and commercialization of existing assets that treat patients with inflammatory disease. Annuncio • Jun 04
Immune Therapeutics, Inc. Announces Board Changes Immune Therapeutics, Inc. announced that it will expand its Board of Directors from two to five members. Joining the Board effective May 31, 2022 will be Dr. Stephen Wilson, Dr. Clifford Selsky, and Mr. Robert Wilson who were appointed for interim terms until such time as an annual meeting of shareholders can be organized to provide a formal vote on the candidates. Dr. Stephen Wilson. Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive management. He is the Chief Innovation Officer of Statera Biopharma, Inc. and an Associate Clinical Professor at the University of California, San Diego. Prior, he served as Chief Operating Officer at the La Jolla Institute for Immunology; during his tenure the Institute grew from $14M in annual R&D to become a global leader in immunology research with nearly $1B in total operations as well as ranked #1 place to work in the world by The Scientist magazine. His original research has been published in high impact journals, and he has served as principal or co-principal investigator on more than $75M in competitive grants and awards, most recently developing the 2021 X-Prize winning rapid CoVID-19 diagnostic test. Dr. Wilson has served as an advisor to elite medical research organizations, served on national boards and is a founding scientist and board member of Invivoscribe Technologies, Inc., a leading molecular diagnostics and oncology therapeutics company. Dr. Wilson earned his doctorate from the University of Arizona’s College of Medicine in Immunology, and was a fellow of the National Multiple Sclerosis Society and National Institutes of Health. Dr. Selsky has been a practicing pediatrician in Central Florida for the past twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital cancer institute, which he established after training in pediatrics at Yale New Haven hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine. Dr. Selsky is board certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013. Also, an accomplished scientist, Dr. Selsky obtained his PH.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the radiobiology laboratory at Harvard School of Public Health and the biophysics laboratory at Stanford University. Mr. Wilson has spent more than 25 years building and launching companies. As a business strategist, retail marketer and content developer, Robert is experienced is assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors, and measuring the results of marketing strategies. Robert has been involved in securing more than $150 million in early round and angel funding, developing launch and pivot strategies, and identifying growth opportunities for more than two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands. Annuncio • May 19
Immune Therapeutics, Inc. announced delayed 10-Q filing On 05/18/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Apr 02
Immune Therapeutics, Inc. announced delayed annual 10-K filing On 03/31/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Jan 28
Immune Therapeutics, Inc. Announces the Resignation of Michael Sander as a Director On January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. Mr. Sander served as director from November 2019.